Name (Synonyms) | Correlation | |
---|---|---|
drug1425 | Macrolide administered for up to 14 days Wiki | 0.71 |
drug1227 | Interferon-β1a Wiki | 0.71 |
drug1424 | Macrolide administered for 3-5 days Wiki | 0.71 |
drug949 | Fixed-duration Hydrocortisone Wiki | 0.71 |
drug1932 | Protocolised mechanical ventilation strategy Wiki | 0.71 |
drug2990 | risk factors Wiki | 0.71 |
drug2254 | Shock-dependent hydrocortisone Wiki | 0.71 |
drug1092 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 0.71 |
drug1820 | Piperacillin-tazobactam Wiki | 0.71 |
drug156 | Amoxicillin-clavulanate Wiki | 0.71 |
drug950 | Fixed-duration higher dose Hydrocortisone Wiki | 0.71 |
drug532 | Ceftriaxone Wiki | 0.71 |
drug946 | Five-days oseltamivir Wiki | 0.71 |
drug1523 | Moxifloxacin or Levofloxacin Wiki | 0.71 |
drug531 | Ceftaroline Wiki | 0.71 |
drug2472 | Ten-days oseltamivir Wiki | 0.71 |
drug2499 | Therapeutic anticoagulation Wiki | 0.50 |
drug217 | Aspirin Wiki | 0.50 |
drug2197 | Sarilumab Wiki | 0.32 |
drug159 | Anakinra Wiki | 0.27 |
drug1374 | Losartan Wiki | 0.25 |
drug1372 | Lopinavir/ritonavir Wiki | 0.22 |
drug2662 | Vitamin C Wiki | 0.21 |
drug658 | Convalescent plasma Wiki | 0.18 |
drug2527 | Tocilizumab Wiki | 0.13 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D016638 | Critical Illness NIH | 0.10 |
D055371 | Acute Lung Injury NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.07 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
D011014 | Pneumonia NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
There are 2 clinical trials
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and not receiving organ support in ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital dischargeThe CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.
Description: Cause of death will be described
Measure: Death Time: up to 28 days of randomisation